Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18267
Country/Region: Haiti
Year: 2016
Main Partner: Partners in Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $6,800,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $738,868
Care: Orphans and Vulnerable Children (HKID) $1,326,188
Care: TB/HIV (HVTB) $401,838
Care: Pediatric Care and Support (PDCS) $365,977
Laboratory Infrastructure (HLAB) $100,000
Strategic Information (HVSI) $106,243
Health Systems Strengthening (OHSS) $103,019
Testing: HIV Testing and Counseling (HVCT) $546,202
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $508,465
Treatment: Adult Treatment (HTXS) $2,355,236
Treatment: Pediatric Treatment (PDTX) $247,964
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 66
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 7
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 66
GEND_GBV Number of people receiving post-GBV care 2017 73
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 4,297
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 4,297
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 72,587
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 52,559
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 133,740
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,185
HTS_TST Service Delivery Point (Facility): Pediatric 2017 8,592
HTS_TST Service Delivery Point (Facility): PMTCT 2017 32,082
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,952
HTS_TST Service Delivery Point (Facility): VCT 2017 89,929
HTS_TST Sum of Aggregated Age/Sex <15 2017 8,594
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 125,146
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 133,740
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 107
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 107
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,022
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,462
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 6,850
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 6,321
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 13,171
PMTCT_ART Already on ART at beginning of current pregnancy 2017 294
PMTCT_ART New on ART 2017 428
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 32,082
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 520
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 200
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 6
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 16
PMTCT_EID Sum of Infant Age disaggregates 2017 720
PMTCT_STAT By: Known positives at entry 2017 300
PMTCT_STAT By: Number of new positives identified 2017 460
PMTCT_STAT Number of new ANC and L&D clients 2017 34,414
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 32,082
PMTCT_STAT Sum of Positives Status disaggregates 2017 760
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 91
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 66
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 161
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 160
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 285
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 86
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 285
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 44
TB_SCREENDX Screen Result: Screened Positive for TB 2017 285
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 7,619
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 5,079
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 350
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 233
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 13,281
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 51
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,123
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 34
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 744
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,952
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,981
TX_CURR Aggregated Age/Sex: <15 Female 2017 350
TX_CURR Aggregated Age/Sex: <15 Male 2017 233
TX_CURR Aggregated Age/Sex: 15+ Female 2017 7,619
TX_CURR Aggregated Age/Sex: 15+ Male 2017 5,079
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 13,281
TX_CURR Sum of Aggregated Age/Sex <15 2017 583
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 12,698
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 13,281
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 88
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 88
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,111
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,524
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 3,831
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 3,811
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 13,281
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 9,962
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 262
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 172
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 5,715
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 3,813
TX_PVLS Numerator: Indication: Routine 2017 8,963
TX_PVLS Numerator: Indication: Targeted 2017 999
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 350
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 233
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 7,619
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 5,079
TX_PVLS_den Denominator: Indication: Routine 2017 11,952
TX_PVLS_den Denominator: Indication: Targeted 2017 1,329
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 94
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 61
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,839
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,071
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 3,065
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,600
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 109
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 72
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,160
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,259
Cross Cutting Budget Categories and Known Amounts Total: $3,670,000
Motor Vehicles: Purchased $100,000
Food and Nutrition: Commodities $250,000
Human Resources for Health $3,100,000
Gender: Gender Based Violence (GBV) $130,000
Post GBV Care
Key Populations: Sex Workers $45,000
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG $45,000
Training of health workers and community outreach workers
Collection and use of strategic information